神经肽Y基因多态性与5-羟色胺再摄取抑制剂疗效关联研究

The Association between Neuropeptide Y Gene Polymorphisms and SSRIs Effect

目的:探讨神经肽Y(NPY)基因多态性rs16147与选择性5-羟色胺再摄取抑制剂(SSRIs)疗效之间的关系。方法:对50例处于发作期、接受SSRIs抗抑郁药物治疗的抑郁症患者,治疗3个月,应用汉密尔顿抑郁量表(HAMD-17)评定其症状严重性,每月评定一次。测定患者NPY基因多态性rs16147,采用重复测量的方差分析判断不同基因型与患者疗效之间的关系。结果:抑郁症患者中,AA基因型9例,AG基因型20例,GG基因型21例。重复测量的方差分析,HAMD评分的基因型效应(F=3.08,P=0.059)和时间效应(F=308.18,P=0.000)。AA基因型的有效率为88.9%,AG基因型的有效率为75.0%,GG基因型的有效率为70.0%。结论:NPYrs16147位点不同基因型之间抗抑郁疗效之间没有显著差异,但A等位基因型的患者疗效优于G等位基因型的患者。

Objective: To explore whether the neuropeptide y gene(NPY),rs16147 polymorphisms was associated with SSRIs effect in the major depressive disorder.Methods: fifty major depressive disorder patients with SSRI,b100d samples were collected from participant for extraction and genotyping.Depressive severity was evaluated by Hamilton depressive sacle-17(HAMD) once a month.Results: Subjects with A/A genotype of NPY polymorphism rs16147 were 9,A/G 20,and G/G 21.There was no effect of genotype on HAMD scores(F=3.08,P=0.059),the treatment time was related to HAMD score(F=308.18,P=0.000).Conclusions: An association of rs16147 with SSRIs effect was not shown.But the response rate was higher in patients with A allele than G.